News | Cardiac Imaging | March 13, 2018

HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology

AutoPlaque technology will accelerate HeartFlow’s efforts to bring plaque assessment to the HeartFlow Analysis

HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology

March 13, 2018 –  HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque based on coronary computed tomography angiography (CCTA) images. HeartFlow plans to use the AutoPlaque technology in its efforts to provide plaque assessment in future products, providing physicians with more information to help diagnose patients with coronary artery disease (CAD) and determine optimal treatment pathways.

The assessment of vulnerable plaque – lesions in coronary arteries that have the potential to rupture and cause acute coronary syndrome (ACS) – is an important area of clinical research. Results of the EMERALD (Exploring the MEchanism of the plaque Rupture in Acute coronary syndrome using coronary CT angiography and computationaL fluidDynamics) study, which were presented at EuroPCR 2016, demonstrated that the HeartFlow® FFRct Analysis, together with an assessment of coronary plaque, may help predict which coronary plaques are most likely to rupture. The HeartFlow FFRct Analysis is a first-of-its-kind non-invasive technology that provides a personalized 3D model of the heart to help clinicians diagnose and treat patients with suspected coronary artery disease (CAD).

“In addition to assessing lesion-specific physiology, understanding and characterizing coronary artery plaque is important in determining the most appropriate treatment path for patients with suspected CAD. The power of utilizing the AutoPlaque tool in the HeartFlow Analysis may accelerate our ability to analyze and characterize plaque in coronary arteries,” said John H. Stevens, M.D., president and chief executive officer, HeartFlow.

CAD, which today affects 16.8 million Americans, develops when the coronary arteries narrow, reducing blood flow to the heart and causing angina (chest pain), myocardial infarction (heart attack) and death. Acute Coronary Syndrome (ACS) is a life-threatening condition that occurs due to decreased blood flow to the heart, often because of a sudden rupture of plaque inside a coronary artery. ACS encompasses both unstable angina and myocardial infarction. In the United States, an ACS occurs every 25 seconds and someone dies from an ACS-related event every minute. Each year, approximately 1.4 million Americans are hospitalized with ACS, of whom 810,000 are hospitalized for myocardial infarction. Studies have shown that plaque rupture causes approximately 75 percent of fatal myocardial infarctions.

About the HeartFlow FFRct Analysis

Clinicians diagnostics someone with suspected CAD want to know as definitively as possible if the individual has a significant blockage in their coronary arteries. They also want to know the impact of that blockage on blood flow so they can best determine which treatment pathway is appropriate (e.g., medical management, stenting or coronary artery bypass grafting).

Data from a patient’s non-invasive CCTA are securely uploaded from the hospital’s system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D model of the patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided via a secure online interface to offer actionable information to enable clinicians to determine the optimal course of treatment. To date, clinicians around the world have used the HeartFlow Analysis for more than 15,000 patients to aid in the diagnosis of heart disease.

This technology has been demonstrated to reduce unnecessary and invasive diagnostic coronary angiography procedures, which can be associated with bleeding, stroke, major blood vessel damage and other serious complications. It also significantly reduces healthcare costs for hospitals.

For more information: www.heartflow.com

Related Content

3-D Reconstruction of Ichthyosaurus Skull

A 3-D reconstruction of the ichthyosaurus skull from a computed tomography (CT) scan. Image courtesy of Nigel Larkin, taken at Royal Veterinary College, London.

News | Computed Tomography (CT) | January 09, 2019
A nearly meter-long skull of a giant fossil marine ichthyosaur found in a farmer's field more than 60 years ago has...
SCCT Releases New Guideline for CT Use During TAVR
News | Computed Tomography (CT) | January 08, 2019
The Society of Cardiovascular Computed Tomography (SCCT) has released a new expert consensus document for computed...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
CT Technique Expands Possibilities of Imaging Ancient Remains
News | Computed Tomography (CT) | December 27, 2018
Researchers in Sweden using computed tomography (CT) have successfully imaged the soft tissue of an ancient Egyptian...
Canon Aquilion One CT Helps Gates Vascular Institute Adhere to New Stroke Guidelines
News | Computed Tomography (CT) | December 12, 2018
In stroke, time saved on imaging is time gained in the treatment window. The recently updated guidelines from the...
Coreline Soft Introduces AI Lung Segmentation Solution at RSNA 2018
News | Lung Cancer | December 10, 2018
December 10, 2018 — Korean image software company Coreline Soft Co. Ltd.
FDA Approves New Features for Planmed Verity Cone Beam CT Scanner
Technology | Computed Tomography (CT) | December 07, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the...
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...